Dr. Daniel M. Schreeder, MD, PHD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 1,017
Licensed in Alabama since 2017, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: University of Alabama School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AL license 35839 (first issued 2017; active) -
Internal Medicine Physician
AL license 5398
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Huntsville Hospital Huntsville, AL
- Crestwood Medical Center Huntsville, AL
- Marshall Medical Centers Boaz, AL
- Highlands Medical Center Scottsboro, AL
Medical groups
- Oncology Specialties, P.c. (109 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,017
- Services billed
- 204,575
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 20,000 | 15 |
| Injection, nivolumab, 1 mg | 19,060 | 12 |
| Injection, denosumab, 1 mg | 9,420 | 52 |
| Injection, aprepitant, 1 mg | 5,980 | 16 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,760 | 11 |
| Injection, ferric derisomaltose, 10 mg | 3,900 | 35 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,522 | 77 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 2,030 | 14 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,852 | 768 |
| Blood test, comprehensive group of blood chemicals | 1,807 | 763 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Huntsville, AL | 229 |
| Eliquis (apixaban) Other prescribers in Huntsville, AL | 209 |
| Ondansetron Hcl Other prescribers in Huntsville, AL | 87 |
| Revlimid (lenalidomide) | 76 |
| Xarelto (rivaroxaban) Other prescribers in Huntsville, AL | 65 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Huntsville, AL | 59 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Huntsville, AL | 54 |
| Dexamethasone Other prescribers in Huntsville, AL | 52 |
| Xtandi (enzalutamide) | 45 |
| Olanzapine Other prescribers in Huntsville, AL | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 58 payments worth $3,199 in total to this clinician.
| Janssen Biotech, Inc. | $1,602 |
|---|---|
| Novartis Pharmaceuticals Corporation | $187 |
| Kite Pharma, Inc. | $165 |
| Genzyme Corporation | $157 |
| Genmab U.S., Inc. | $142 |
| GlaxoSmithKline, LLC. | $112 |
| Daiichi Sankyo Inc. | $107 |
| Pfizer Inc. | $100 |
| Food and Beverage | $1,639 |
|---|---|
| Consulting Fee | $1,540 |
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Apr 16, 2025 | Consulting Fee TECVAYLI · Oncology | $1,540 |
| Aveo Pharmaceuticals, Inc. Apr 29, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $3,800 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
Ipsen Bioscience Inc. · Completed · NCT04083235 - EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
Jazz Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.